Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.42 |
| ▸ | PARP1 | P09874 | 6/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | F3 | P13726 | 1/20 | 0.40 |
| ▸ | PARP11 | Q9NR21 | 5/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 3/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21768121 | 0.92 | PARP10 (0.42) | PARP10PARP1PARP11PDPK1 | |
| SCHEMBL28513382 | 0.86 | PARP1 (0.38) | PARP10PARP1F7F3CD274 | |
| SCHEMBL28901217 | 0.81 | PARP10 (0.42) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL28658786 | 0.79 | PARP11 (0.37) | PARP10PARP1PARP11 | |
| SCHEMBL28499172 | 0.79 | PARP11 (0.37) | PARP10PARP1PARP11 | |
| SCHEMBL28655211 | 0.79 | PARP11 (0.37) | PARP10PARP1PARP11 | |
| SCHEMBL21768178 | 0.78 | CYP26A1 (0.33) | — | |
| SCHEMBL21768338 | 0.74 | AOC3 (0.43) | PARP10PARP1F7F3 | |
| SCHEMBL28979238 | 0.74 | KCNH2 (0.42) | CTSC | |
| SCHEMBL28901241 | 0.72 | PARP11 (0.40) | PARP10PARP1PARP11PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087248-A1 | Fluoroallylamine Derivative And Use Thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-03-19 | — | — | US | disclosed |
| EP-3617186-A1 | FLUOROALLYLAMINE DERIVATIVE AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087248-A1 | Fluoroallylamine Derivative And Use Thereof | VAPB, VAPA, SLC28A1 | PARP10 2655/4885PARP1 2532/4885F7 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.